financetom
Business
financetom
/
Business
/
EaseMyTrip aims to outpace market growth rate, focus on profitability
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
EaseMyTrip aims to outpace market growth rate, focus on profitability
Nov 21, 2023 6:23 AM

EaseMyTrip.com, operated by Easy Trip Planners, wants to focus on enhancing profitability in the current fiscal year. The travel-tech platform is targeting a compound annual growth rate (CAGR) that's double the market's expected 10-15%, according to Co-founder Prashant Pitti.

Share Market Live

NSE

“We are in a market that is going to grow at a CAGR of more than 14-15% on an annual basis for the next 10 years. At EaseMyTrip, we are striving to grow at double the pace of the market," he stated.

Pitti said the company’s gross merchandise volume (GMV) was about ₹8,000 crore last year. The focus this year will be more on profitability while continuing to expand the GMV, albeit not at an exponential pace like before.

GMV for travel portals refers to the total value of all travel-related bookings and services sold through the platform over a specific period. This typically includes the value of airline tickets, hotel bookings, holiday packages, and other travel services before deducting any discounts or returns.

Read Here | EaseMyTrip envisions hotel business reaching breakeven or profitability in near future

Pitti also talked about the exclusive subscription programme launched by the company that invites high-net-worth individuals (HNIs) and CEOs to explore specialised services.

The new EaseMyTrip Platinum, Gold, and Silver Cards are designed to make travel more luxurious and convenient. The decision to launch these subscription plans was driven by strong consumer demand, Pitti said.

Also Read | India sees 10 lakh flyers over Diwali weekend, travel portals witness sharp uptick in demand

The company's net profit shot up nearly 67%% over the last year to ₹471.78 crore in the second quarter of the financial year 2024. Revenue from operations came in at ₹1,416.94 crore, a growth of over 30% from ₹1,084.99 crore a year ago.

The Delhi-based company has a market capitalisation of ₹7,138 crore and it competes with other travel majors such as Thomas Cook, Yatra Online and MakeMyTrip.

(Edited by : Shweta Mungre)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Gatos Silver, First Majestic Get Regulatory Approval for Merger
Gatos Silver, First Majestic Get Regulatory Approval for Merger
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Gatos Silver ( GATO ) said Friday that the proposed acquisition of the company by First Majestic (AG) was given unconditional authorization by the Mexican Federal Economic Competition Commission. The transaction is expected to close in January. ...
Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal
Berkshire Hills Bancorp and Brookline to merge in $1.1 bln deal
Dec 16, 2024
Dec 16 (Reuters) - Regional lenders Berkshire Hills Bancorp ( BHLB ) and Brookline Bancorp ( BRKL ) have agreed to merge in an all-stock deal valued at about $1.1 billion, the companies said on Monday. ...
Healwell Acquires New Zealand-based Orion Health for $165 Million
Healwell Acquires New Zealand-based Orion Health for $165 Million
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Healwell AI (AIDX.TO) on Monday said it will acquire New Zealand-based Orion Health Holdings for $165 million, with a minimum $86 million in cash and the remainder in stock. The cash portion of the acquisition price will be partially funded by a bought deal private placement of 31,250 convertible debentures at $960 each...
Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial
Biohaven Says BHV-1300 Achieves 'Deep Lowering' of Targeted IgG During Early-Stage Trial
Dec 16, 2024
08:32 AM EST, 12/16/2024 (MT Newswires) -- Biohaven ( BHVN ) said Monday that its drug candidate BHV-1300 achieved deep lowering of targeted immunoglobulin G, or IgG, with reduction of more than 60% in the lowest subcutaneous dose tested during the current multiple ascending dose trial. The biopharmaceutical company said that the reduction in IgG occurred within hours of each...
Copyright 2023-2026 - www.financetom.com All Rights Reserved